In OSCC specifically, Tripathi et al. [37] conducted a meta-analysis restricted to immunohistochemical CSC markers—mainly CD44, CD24, CD133, and ALDH—and reported that CD133 expression was associated with poorer survival, whereas ALDH expression correlated with lymph node metastasis and advanced clinical stage. The gene discussed is PROM1; the disease is metastatic malignant neoplasm in the lymph nodes.